Name: 글로벌 시장 동향
SKU: PH7472
Availability: InStock

보고서 요약(국문)

개요
전 세계 성교통 치료제 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
성교통은 성관계 전, 중 또는 후에 발생할 수 있는 생식기 통증으로 정의됩니다. 특정 원인을 규명하는 것이 어려워 성 장애 또는 통증 장애로 분류하는 것에 대해서는 논란이 있습니다. 성교통은 신체적, 정신적 건강 및 삶의 질에 상당한 영향을 미칠 수 있습니다. 본 활동은 성교통의 평가 및 관리를 설명하고, 이 질환을 가진 환자 관리에 있어 다학제 팀의 역할을 강조합니다.
성교통의 원인은 구조적, 염증성, 감염성, 종양성, 외상성, 호르몬성 및 심리사회적 요인을 포함합니다. 해부학적 원인으로는 골반저근 기능 장애, 자궁 후굴, 처녀막 잔존, 골반 장기 탈출증 등이 있습니다. 질 윤활 부족은 가임기 여성에게 가장 흔하며 호르몬 및 성적 흥분 장애와 관련이 있습니다.
시장 동향: 동인 및 제약 요인
질병에 대한 인식 증가
질병에 대한 인식 증가는 예측 기간 동안 시장 성장에 도움이 되는 중요한 요인 중 하나입니다. 약사는 성교통에 대한 인식을 높이고 폐경 후 여성에게 성교통 치료 옵션, 특히 중등도에서 중증 성교통을 겪는 여성을 위한 질내 주사(intrarosa)에 대한 구체적인 정보를 제공하는 데 있어 중요한 역할을 할 수 있습니다. 폐경 후 여성에게서 질 위축증(VVA)에 대한 대화를 시작하기 어려운 경우가 많다는 점을 고려할 때, 이 민감한 질환에 대한 논의를 방해할 수 있는 요인을 이해하는 약사는 적절한 시기에 환자와 대화를 시작하는 데 더 효과적일 수 있습니다.

예를 들어, 2023년 8월, 여성 건강 분야 비상장 기업인 애저 바이오테크(Azure Biotech, Inc.)는 외음부 질 위축증(VVA) 치료를 위한 라소폭시펜의 새로운 제형을 개발하면서, 수백만 명의 여성에게 영향을 미치는, 제대로 된 치료를 받지 못하는 이 폐경기 질환을 가진 여성들을 지원하기 위한 교육 캠페인을 시작했습니다.
미국 국립보건원(NIH)에 따르면 여성은 인생의 30~40%를 폐경기에 보내지만, 폐경, 증상, 질환 및 치료법에 대한 논의는 동료, 배우자, 의사, 심지어 언론에서도 공개적으로 이루어지지 않는 경우가 많습니다. 애저의 캠페인 목표는 이러한 대화를 시작하고 대중을 교육하는 것입니다. 애저는 이러한 소외된 커뮤니티에 유용한 자료를 제공하는 웹사이트 whatsVVA.com을 개설했습니다.
시장 동향: 제약
성교통은 일반적으로 치료 가능한 질환이며 몇 가지 합병증을 동반할 수 있습니다. 질환의 양성 여부와 관계없이, 고통스러운 후유증을 예방하기 위해서는 시기적절한 관리와 개입이 매우 중요합니다. 환자들이 신속하고 적절한 치료를 받지 않으면 성욕 감퇴와 관계 문제로 이어질 수 있습니다. 또한 파트너 간에 심각한 고통과 갈등을 초래할 수 있습니다. 성교통은 환자의 정신적, 신체적 건강, 신체 이미지, 관계, 임신 노력에 부정적인 영향을 미칠 뿐만 아니라 성욕 및 성적 흥분 감소를 유발할 수 있습니다.
세분화 분석
전 세계 성교통 치료제 시장은 질병 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
약물 계열 중 에스트로겐 계열은 성교통 치료제 시장 점유율의 약 41.7%를 차지했습니다.
에스트로겐 계열은 약 41.7%의 점유율을 차지하며 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 에스트로겐은 여성 생식 기관과 관련된 스테로이드 호르몬으로 여성의 성적 특징 발달에 관여합니다. 에스트로겐 또는 에스트라디올은 FDA 승인을 받은 호르몬 대체 요법(HRT)으로 폐경과 관련된 증상을 관리하는 데 가장 흔하게 사용되는 에스트로겐 호르몬 형태입니다.
예를 들어, 2022년 2월, 여성 건강 전문 제약 회사이자 퀘벡주 블랭빌에 본사를 둔 뒤셰네 제약 그룹의 계열사인 뒤셰네(Duchesnay Inc.)는 새로운 소유주와 경영진이 캐나다 전역의 폐경 후 여성들의 질 건조증과 성교통 완화를 위해 출시한 첫 번째 치료제를 발표했습니다. 선택적 에스트로겐 수용체 조절제(SERM)인 오스페나(오스페미펜 정제)는 캐나다 보건부의 승인을 받아 해당 질환에 대한 1일 1회 처방 치료제로 현재 캐나다 전역에서 구입할 수 있습니다.

지리적 분석
북미는 2022년 시장 점유율의 약 38.4%를 차지했습니다.
북미는 인식 개선 프로그램 출시, 주요 업체와의 협력 및 계약, 첨단 의료 기술, 연구 개발, 공공 인식 캠페인 등을 통해 예측 기간 동안 전체 시장 점유율의 약 38.4%를 차지할 것으로 예상되며, 이는 해당 지역이 예측 기간 동안 가장 높은 시장 점유율을 기록할 것으로 전망되는 요인입니다.
예를 들어, 여성 건강 전문 제약 회사인 Duchesnay USA는 2020년 6월, '솔직한 이야기: 폐경기 여성의 성생활(Straight Talk: Sex and the Menopausal Woman)'이라는 제목의 새로운 영상을 출시했습니다. 50세 이상 여성을 위한 선도적인 온라인 플랫폼인 FabOverFifty와 공동 제작한 이 영상은 폐경기로 인한 중등도에서 중증의 질 건조증 및 성교통에 대한 정보를 제공하기 위해 Duchesnay USA에서 제공하는 일련의 영상 중 최신 영상입니다.

또한, 2020년 5월, 밀리센트 파마 경영진과 칼라일 그룹이 설립한 글로벌 제약회사인 밀리센트 파마 리미티드는 혁신적인 제품을 통해 미충족 의료 수요를 가진 환자들을 지원하는 데 주력하는 제약회사인 AMAG Pharmaceuticals, Inc.로부터 인트라로사(프라스테론)의 미국 내 상업화 권리를 인수하는 최종 계약을 체결했다고 발표했습니다. 인트라로사는 폐경기에 나타나는 외음부 및 질 위축의 증상인 중등도에서 중증의 성교통 치료에 사용되는 스테로이드제입니다.
COVID-19 영향 분석
COVID-19는 여성의 성생활 및 성관계 빈도, 스트레스 및 불안 수준에 영향을 미쳐 성교통 치료제 시장에 상당한 영향을 미쳤습니다. 연구 결과, 파트너 관계 악화와 스트레스 및 불안 수준 증가가 팬데믹과 관련이 있는 것으로 나타났습니다. 의사는 병력 청취 후 필요에 따라 심리 치료를 제안하고, 이 어려운 시기에 성 전문가와의 상담을 용이하게 하기 위해 원격 진료를 고려해야 합니다.

시장 세분화
질병 유형별
• 표재성 성교통
• 심부 성교통
약물 종류별
• 에스트로겐
• 선택적 에스트로겐 수용체 조절제
• 기타 질 제제
• 기타
투여 경로별
• 경구
• 질 삽입제
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 업체로는 Pfizer, Therapeutics MD, Myovant, Novo Nordisk, Duchesnay USA Inc, Maynepharma 등이 있습니다. Manus Aktteva Biopharma LLP, Lupin Pharma Canada, Verity Pharma, Teva Pharmaceuticals 등이 참여하고 있습니다.

주요 개발 사항
 2023년 1월, Lupin Pharma Canada는 폐경 후 외음부 질 위축증 치료제인 Intrarosa®(프라스테론 질 좌약)를 출시한다고 발표했습니다. 이 치료제는 성교통, 질 건조증, 자극 및 가려움증과 같은 폐경기 증상을 완화하는 데 도움을 줍니다. 또한, Intrarosa®는 독특한 작용 기전을 통해 에스트로겐과 안드로겐 결핍을 모두 표적으로 삼아 신속한 효과를 보이며 안전성 또한 뛰어납니다.

 2022년 2월 14일, 퀘벡주 블랭빌에 본사를 둔 Duchesnay Pharmaceutical Group의 계열사이자 여성 건강 전문 제약 회사인 Duchesnay, Inc.는 캐나다 전역에서 폐경 후 여성의 질 건조증 및 성교통 완화를 위한 최초의 치료제를 출시한다고 발표했습니다. 캐나다 전역에서 시판 중인 선택적 에스트로겐 수용체 조절제(SERM)인 오스페나(오스페미펜 정제)는 캐나다 보건부(Health Canada)의 승인을 받아 1일 1회 복용하는 성교통 치료제로 사용 가능합니다.
보고서 구매 이유:

• 질병 유형, 약물 종류, 투여 경로, 유통 채널 및 지역별 글로벌 성교통 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악할 수 있습니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.

• 모든 세그먼트를 포함한 성교통 치료제 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑 자료를 제공합니다.

글로벌 성교통 치료제 시장 보고서는 약 69개의 표, 58개의 그림, 187페이지 분량입니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Dyspareunia Drugs Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY % during the forecast period 2023-2030.
Dyspareunia is defined by genital pain that can be experienced before, during, or after intercourse. It is debatable whether this condition can be classified as a sexual disorder or pain disorder as identifying a specific etiology can prove challenging. Dyspareumia can have a significant effect on physical and mental health, as well as quality of life. This activity illustrates the evaluation and management of dyspareunia and highlights the role of the interprofessional team in managing patients with this condition.
The etiology of dyspareunia encompasses structural, inflammatory, infectious, neoplastic, traumatic, hormonal, and psychosocial conditions. Anatomic causes include pelvis floor muscle dysfunction, uterine retroversion, hymenal remnants, and pelvic organ prolapse. Lack of lubrication is most common in reproductive years and is attributable to hormonal as well as sexual arousal disorders.
Market Dynamics: Drivers and Restraints
Increasing awareness about the disease
Increasing awareness about the disease is one of the significant key factors that help the market during the forecast period. Pharmacists are uniquely positioned to address the unmet need for dyspareunia awareness and to counsel postmenopausal women on available treatment options for dyspareunia, including specific information regarding intrarosa for those with moderate to severe dyspareunia. Given that there often is a failure to initiate conversations around VVA in the postmenopausal population, pharmacists with an understanding of potential barriers to discussing this sensitive condition may be better equipped to initiate conversations with patients when appropriate.
For instance, in August 2023, Azure Biotech, Inc., a privately held women’s health company that is developing novel formulations of lasofoxifene for vulvovaginal atrophy (VVA), launched an educational campaign to support women with this underserved menopausal health condition affecting millions of women.
According to the National Institutes of Health, women spend 30-40% of their lives in menopause, yet the topic of menopause, symptoms, conditions, and treatments is typically not openly discussed among peers, partners, doctors, and even in the media. The objective of Azure’s campaign is to open this dialog and educate the public. Azure has created a website, whatsVVA.com providing valuable resources to this underserved community.
Market Dynamics: Restraint
Dyspareunia is usually a treatable disease and has some complications. Regardless of the non-malignant nature of the disease, timely management and intervention are crucial to obviate distressing sequelae. If the patients do not seek prompt, appropriate medical care, it can result in loss of sexual interest and problems with relationships. It also results in significant distress and conflicts among the partners. Dyspareunia can lead to negative impacts on a patient's mental and physical health, body image, relationships, and conceiving efforts, as well as decreased libido and arousal.
Segment Analysis
The global dyspareunia drugs market is segmented based on disease type, drug type, route of administration, distribution channel and region.
The estrogen segment from the drug class segment accounted for approximately 41.7% of the dyspareunia drugs market share
The estrogen segment from the drug class segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Estrogen is a steroid hormone associated with the female reproductive organs and is responsible for developing female sexual characteristics. Estrogen or estradiol is the most common form of estrogen hormone for FDA-approved treatment as hormone replacement therapy (HRT) in managing symptoms associated with menopause.
For instance, in February 2022, Duchesnay Inc., a pharmaceutical company specializing in women's health and part of the Duchesnay pharmaceutical group based in Blainville, Quebec, stated that the first treatment launched by its new ownership and management team to help postmenopausal women across Canada who are suffering from vaginal dryness and painful intercourse. Osphena (ospemifene tablets), a Selective Estrogen Receptor Modulator (SERM) now available across Canada, has been approved by Health Canada as a once-daily prescription treatment for this indication.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the awareness program launches, collaborations and agreements with key players, advanced medical technology, research and development, public awareness campaigns and others that will drive this region to be highest market share during the forecast period.
For instance, in June 2020, Duchesnay USA, a pharmaceutical company that specializes in women's health, is proud to announce the launch of a new video titled Straight Talk: Sex and the Menopausal Woman. Produced in collaboration with FabOverFifty, a leading online platform for women over 50, this video is the latest in a series of videos offered by Duchesnay USA to educate women about moderate to severe vaginal dryness and dyspareunia due to menopause.
Moreover, in May 2020, Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group, stated a definitive agreement to acquire the U.S. commercial rights to Intrarosa (prasterone) from AMAG Pharmaceuticals, Inc. a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. Intrarosa is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
COVID-19 Impact Analysis
Covid 19 had a substantial impact on the dyspareunia drugs market where the impact of the COVID-19 pandemic on women's sexual life and frequency of intercourse, as well as stress and anxiety levels. The study also found that deteriorating partner relationships and increased stress and anxiety levels were linked to the pandemic. Doctors should provide anamnesis suggest psychotherapy if applicable, and consider telemedicine for facilitating contact with sexologists during this challenging time.
Market Segmentation
By Disease Type
• Superficial Dyspareunia
• Deep Dyspareunia
By Drug Class
• Estrogens
• Selective Estrogen Receptor Modulators
• Miscellaneous Vaginal Agents
• Others
By Route of Administration
• Oral
• Vaginal Inserts
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Pfizer, Therapeutics MD, Myovant, Novo Nordisk, Duchesnay USA Inc, Maynepharma, Manus Aktteva Biopharma LLP, Lupin Pharma Canada, Verity Pharma, Teva Pharmaceuticals and among others.
Key Developments
 In January 2023, Lupine Pharma Canada stated the launch of a novel treatment for postmenopausal vulvovaginal atrophy called Intrarosa@ (prasterone vaginal ovules). Dyspareunia (painful intercourse), vaginal dryness, irritation, and itching are symptoms of menopause that are managed with this treatment. Additionally, Intrarosa@, which has a unique mode of action, responds quickly and has a safe profile, as it targets both estrogen and androgen deficiencies.
 On February 14, 2022, Duchesnay, Inc., a pharmaceutical company specializing in women's health and part of the Duchesnay Pharmaceutical Group based in Blainville, Quebec, announced the first treatment launched to help postmenopausal women suffering from vaginal dryness and painful intercourse across Canada. Osphena (ospemifene tablets), a Selective Estrogen Receptor Modulator (SERM) now available across Canada, has been approved by Health Canada as a once-daily prescription treatment for this indication.
Why Purchase the Report?
• To visualize the global dyspareunia drugs market segmentation based on disease type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of dyspareunia drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global dyspareunia drugs market report would provide approximately 69 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing awareness about the disease
4.1.1.2. Novel drug launches
4.2. Restraints
4.2.1.1. Complications associated with the drugs
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Superficial Dyspareunia *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Deep Dyspareunia
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class
8.2. Estrogens *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Selective Estrogen Receptor Modulators
8.4. Miscellaneous Vaginal Agents
8.5. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Vaginal Inserts
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Pfizer *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Therapeutics MD
13.3. Myovant
13.4. Novo Nordisk
13.5. Duchesnay USA Inc
13.6. Maynepharma
13.7. Manus Aktteva Biopharma LLP
13.8. Lupin Pharma Canada
13.9. Verity Pharma
13.10. Teva Pharmaceuticals
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Pfizer, 4.	Key Developments, Therapeutics MD, Myovant, Novo Nordisk, Duchesnay USA Inc, Maynepharma, Manus Aktteva Biopharma LLP, Lupin Pharma Canada, Verity Pharma, Teva Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Dyspareunia Drugs Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Dyspareunia Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Dyspareunia Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Dyspareunia Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Dyspareunia Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Dyspareunia Drugs Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Dyspareunia Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 8 Global Dyspareunia Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Dyspareunia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 10 Global Dyspareunia Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Dyspareunia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 12 Global Dyspareunia Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Dyspareunia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Dyspareunia Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Dyspareunia Drugs Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Dyspareunia Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 17 North America Dyspareunia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 18 North America Dyspareunia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 North America Dyspareunia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Dyspareunia Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Dyspareunia Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 22 South America Dyspareunia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 23 South America Dyspareunia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 24 South America Dyspareunia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Dyspareunia Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Dyspareunia Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 27 Europe Dyspareunia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 28 Europe Dyspareunia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 Europe Dyspareunia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Dyspareunia Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Dyspareunia Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Dyspareunia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Dyspareunia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Dyspareunia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Dyspareunia Drugs Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Dyspareunia Drugs Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Dyspareunia Drugs Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Dyspareunia Drugs Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Dyspareunia Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 Pfizer: Overview

Table 41 Pfizer: Product Portfolio

Table 42 Pfizer: Key Developments

Table 43 Therapeutics MD: Overview

Table 44 Therapeutics MD: Product Portfolio

Table 45 Therapeutics MD: Key Developments

Table 46 Myovant: Overview

Table 47 Myovant: Product Portfolio

Table 48 Myovant: Key Developments

Table 49 Novo Nordisk: Overview

Table 50 Novo Nordisk: Product Portfolio

Table 51 Novo Nordisk: Key Developments

Table 52 Duchesnay USA Inc: Overview

Table 53 Duchesnay USA Inc: Product Portfolio

Table 54 Duchesnay USA Inc: Key Developments

Table 55 Maynepharma: Overview

Table 56 Maynepharma: Product Portfolio

Table 57 Maynepharma: Key Developments

Table 58 Manus Aktteva Biopharma LLP: Overview

Table 59 Manus Aktteva Biopharma LLP: Product Portfolio

Table 60 Manus Aktteva Biopharma LLP: Key Developments

Table 61 Lupin Pharma Canada: Overview

Table 62 Lupin Pharma Canada: Product Portfolio

Table 63 Lupin Pharma Canada: Key Developments

Table 64 Verity Pharma: Overview

Table 65 Verity Pharma: Product Portfolio

Table 66 Verity Pharma: Key Developments

Table 67 Teva Pharmaceuticals: Overview

Table 68 Teva Pharmaceuticals: Product Portfolio

Table 69 Teva Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 2 Global Dyspareunia Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 3 Global Dyspareunia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 4 Global Dyspareunia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Dyspareunia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Dyspareunia Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Dyspareunia Drugs Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 8 Superficial Dyspareunia Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 9 Deep Dyspareunia Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 10 Global Dyspareunia Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 11 Estrogens Drug Class in Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 12 Selective Estrogen Receptor Modulators Drug Class in Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 13 Miscellaneous Vaginal Agents Drug Class in Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 14 Others Drug Class in Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 15 Global Dyspareunia Drugs Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 16 Oral Route of Administration in Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 17 Vaginal Inserts Route of Administration in Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 18 Global Dyspareunia Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 19 Hospital Pharmacies Distribution Channel in Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 20 Retail Pharmacies Distribution Channel in Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 21 Online Pharmacies Distribution Channel in Global Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 22 Global Dyspareunia Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 24 Asia-Pacific Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 25 Europe Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 26 South America Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 27 Middle East and Africa Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 28 North America Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 29 North America Dyspareunia Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 30 North America Dyspareunia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 31 North America Dyspareunia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 32 North America Dyspareunia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 33 North America Dyspareunia Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 34 South America Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 35 South America Dyspareunia Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 36 South America Dyspareunia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 37 South America Dyspareunia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 38 South America Dyspareunia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 39 South America Dyspareunia Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 40 Europe Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 41 Europe Dyspareunia Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 42 Europe Dyspareunia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 43 Europe Dyspareunia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Europe Dyspareunia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Europe Dyspareunia Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 46 Asia-Pacific Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 47 Asia-Pacific Dyspareunia Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 48 Asia-Pacific Dyspareunia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 49 Asia-Pacific Dyspareunia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 50 Asia-Pacific Dyspareunia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 51 Asia-Pacific Dyspareunia Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 52 Middle East & Africa Dyspareunia Drugs Market Value, 2021-2030 (US$ Million)

Figure 53 Middle East & Africa Dyspareunia Drugs Market Share, By Disease Type, 2022 & 2030 (%)

Figure 54 Middle East & Africa Dyspareunia Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 55 Middle East & Africa Dyspareunia Drugs Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 56 Middle East & Africa Dyspareunia Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 57 Pfizer: Financials

Figure 58 Therapeutics MD: Financials

Figure 59 Myovant: Financials

Figure 60 Novo Nordisk: Financials

Figure 61 Duchesnay USA Inc: Financials

Figure 62 Maynepharma: Financials

Figure 63 Manus Aktteva Biopharma LLP: Financials

Figure 64 Lupin Pharma Canada: Financials

Figure 65 Verity Pharma: Financials

Figure 66 Teva Pharmaceuticals: Financials

세계 성교통 치료제 시장 – 2023-2030

Global Dyspareunia Drugs Market - 2023-2030